The Hepatoprotective Effect and Its Possible Mechanism of Picroside II in ApoE-/- Mice of Atherosclerosis

Zishan Liu¹, Yuqin Ren², Lin Zhu³, Yong Hu¹, Min Qi³, Yunliang Guo^1, and Jinbao Zong^3,

¹Institute of Integrate Medicine, Qingdao Hiser Hospital Affiliated to Qingdao University, Qingdao 266021, China

²Department of Physiology, Basic School of Qingdao University, Qingdao 266071, China

³2Department of Physiology, Basic School of Qingdao University, Qingdao 266071, China

Cite this paper:
Zishan Liu, Yuqin Ren, Lin Zhu, Yong Hu, Min Qi, Yunliang Guo and Jinbao Zong. The Hepatoprotective Effect and Its Possible Mechanism of Picroside II in ApoE-/- Mice of Atherosclerosis. Journal of Food and Nutrition Research. 2024; 12(3):144-150. doi: 10.12691/jfnr-12-3-6

Abstract

Objective: To investigate the hepatoprotective effect and possible mechanism of picroside II in ApoE-/- mice of atherosclerosis. Methods: ApoE-/- mice fed with high-fat diet for 12 weeks were randomly divided into model group, low-, medium- and high-dose of picroside II groups and positive-drug (praluent) group, C57BL/6J mice fed with ordinary feed were the control group. After modeling, Picroside II (5, 20, 40 mg/kg/d) was injected intraperitoneally in treatment group, and praluent (10 mg/kg/w) was given intraperitoneally in the positive-drug group for 12 weeks. The remaining groups were given equal volume saline. Serum total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) were detected by biochemical assay. The aortic wall lipid deposition and collagen fibers in liver tissue were respectively observed by oil red O staining and Masson staining, the liver function was observed by measuring the content ofGlutamic-oxal (o)acetic transaminase（GOT）and Glutamic-pyruvic transaminase（GPT）and Western blot was used to detect PI3K/Akt pathway and levels of the inflammatory factor interleukin-6 (IL-6) protein. Results: In the control, mice had better mental state and bright fur, while the mental state of mice fed with high-fat diet was slightly worse and more obese. After the end of the administration cycle, compared with the model group, the body weight of mice in the medium and high dose groups and the praluentr group was significantly decreased (P<0.01), the serum levels of TG, TC and LDL-C were significantly decreased (P<0.05) while the HDL-C levels were significantly increased (P<0.05), the lipid deposition area and the collagen volume fraction in liver tissue were significantly decreased (P<0.05), the expressions of PI3K, Akt and IL-6 were significantly decreased (P<0.05). Conclusion: Picroside II could improve lipid metabolism, improve liver fibrosis, which might related to inhibiting the activation of PI3K/Akt signaling pathway.

Keywords:
Picroside II atherosclerosis hepatic fibrosis inflammation PI3K/Akt signaling pathway

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Dis Primers, 2019,5(1): 56.
[2]	Libby P. The changing landscape of atherosclerosis. Nature, 2021,592(7855): 524-533.
[3]	Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2022 update: A report from the American Heart Association. Circulation, 2022,145(8): e153-e639.
[4]	Duell PB, Welty FK, Miller M, et al. Nonalcoholic fatty liver disease and cardiovascular risk: A scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol, 2022, 42(6):e168-e185.
[5]	Barbarroja N, Ruiz-Ponce M, Cuesta-López L, et al. Nonalcoholic fatty liver disease in inflammatory arthritis: Relationship with cardiovascular risk. Front Immunol, 2022,13:997270.
[6]	Ballestri S, Lonardo A, Bonapace S, et al. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol, 2014, 20(7): 1724-1745.
[7]	Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol, 2019,71(4): 793-801.
[8]	Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol, 2018,14(2): 99-114.
[9]	Wang C, Ma C, Fu K, et al. Phillygenin attenuates carbon tetrachloride-induced liver fibrosis via modulating inflammation and gut microbiota. Front Pharmacol, 2021,12: 756924.
[10]	Poznyak AV, Sukhorukov VN, Zhuravlev A, et al. Modulating mTOR signaling as a promising therapeutic strategy for atherosclerosis. Int J Mol Sci, 2022,23(3): 1153-1153.
[11]	Frangogiannis N. Transforming growth factor-β in tissue fibrosis. J Exp Med, 2020, 217(3): e20190103.
[12]	Hamidi A, Song J, Thakur N, et al. TGF-β promotes PI3K-AKT signaling and prostate cancer cell migration through the TRAF6-mediated ubiquitylation of p85α. Sci Signal, 2017, 10(486):eaal4186.
[13]	Jafari M, Ghadami E, Dadkhah T, et al. PI3k/AKT signaling pathway: Erythropoiesis and beyond. J Cell Physiol, 2019,234(3):2373-2385.
[14]	Li ZX, Sheng XD, Wang YL, et al. Blocking P2X4 purinergic receptor attenuates alcohol-related liver fibrosis by inhibiting hepatic stellate cell activation through PI3K/AKT signaling pathway. Int Immunopharmacol, 2022,113(Pt A):109326.
[15]	Chen Z, Lin Z, Yu J, et al. Mitofusin-2 resrtrains hepatic stellate cells' proliferation via PI3K/Akt signaling pathway and inhibits liver fibrosis in rats. J Healthc Eng, 2022,2022: 6731335.
[16]	Lee SW, Kim SM, Hur W, et al. Tenofovir disoproxil fumarate directly ameliorates liver fibrosis by inducing hepatic stellate cell apoptosis via downregulation of PI3K/Akt/mTOR signaling pathway. PLoS One, 2021,16(12): e0261067.
[17]	Li Y, Wang L, Chen Z, et al. Picroside II attenuates ischemia/reperfusion testicular injury by alleviating oxidative stress and apoptosis through reducing nitric oxide synthesis. Acta Cir Bras, 2019, 34(11): e201901102.
[18]	Wang Y, Hong Y, Zhang C, et al. Picroside II attenuates hyperhomocysteinemia-induced endothelial injury by reducing inflammation, oxidative stress and cell apoptosis. J Cell Mol Med, 2019, 23(1): 464-475.
[19]	Wang L, Liu XH, Chen H, et al. Picroside II protects rat kidney against ischemia/reperfusion-induced oxidative stress and inflammation by the TLR4/NFκB pathway. Exp Ther Med, 2015, 9(4): 1253-1258.
[20]	Liu ZS, Zhang YX, Wu XL, et al. The neuroprotective effect and possible mechanism of picroside II against oxygen glucose deprivation/reoxygenation cell model. J Food Nutr Res, 2023, 11(11): 700-706.
[21]	Lee K, Choi J, Choi BK, et al. Picroside II isolated from Pseudolysimachion rotundum var. subintegrum inhibits glucocorticoid refractory serum amyloid A (SAA) expression and SAA-induced IL-33 secretion. Molecules, 2019, 24(10): 2020.
[22]	Ivan E, Khatri JJ, Johnson C, et al. Expansive arterial remodeling is associated with increased neointimal macrophage foam cell content: the murine model of macrophage-rich carotid artery lesions. Circulation, 2002,105(22): 2686-2691.
[23]	Li J, Lin S, Vanhoutte PM, et al. Akkermansia Muciniphila protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in ApoE-/- mice. Circulation, 2016, 133(24): 2434-2446.
[24]	Han Y, Chen J, Chopra VK, et al. ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand. J Clin Lipidol, 2020,14(1): 98-108.e8.
[25]	Fan J, Watanabe T. Atherosclerosis: Known and unknown. Pathol Int, 2022,72(3): 151-160.
[26]	Liu L, Shi Z, Ji X, et al. Adipokines, adiposity, and atherosclerosis. Cell Mol Life Sci, 2022, 79(5): 272.
[27]	Julin MT, Pera G, Soldevila B, et al. Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study. Eur J Endocrinol, 2021,184(4): 587-596.
[28]	Liberale L, Bonaventura A, Vecchi A, et al. The role of adipocytokines in coronary atherosclerosis. Curr Atheroscler Rep, 2017,19(2): 10.
[29]	Ji Haijie, Hao Shulan, Lv Lin, etc Research progress on cucurbitane type tetracyclic triterpenoids from Picrorhiza chinensis and their biological activities. Chine Herb Med, 2022,53 (15): 4875-4881.
[30]	Ediriweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance. Semin Cancer Biol, 2019, 59: 147-160.
[31]	Ghomlaghi M, Yang G, Shin SY, et al. Dynamic modelling of the PI3K/MTOR signalling network uncovers biphasic dependence of mTORC1 activity on the mTORC2 subunit SIN1. PLoS Comput Biol, 2021,17(9): e1008513.
[32]	Jia W, Liu J, Tian X, et al. MircoRNA-126-5p inhibits apoptosis of endothelial cell in vascular arterial walls via NFκB/PI3K/AKT/mTOR signaling pathway in atherosclerosis. J Mol Histol, 2022, 53(1): 51-62.
[33]	Song T, Chen WD. Berberine inhibited carotid atherosclerosis through PI3K/AKTmTOR signaling pathway. Bioengineered, 2021,12(1): 8135-8146.
[34]	Wang L, Wu T, Si C, et al. Danlou tablet activates autophagy of vascular adventitial fibroblasts through PI3K/Akt/mTOR to protect cells from damage caused by atherosclerosis. Front Pharmacol, 2021,12: 730525.